Podcasts about pal

SEASON 4 EPISODE 23: COUNTDOWN WITH KEITH OLBERMANN A-Block (2:30) SPECIAL COMMENT: Here we go again. Trump is talking about his own mortality or career mortality or heaven or all of the above… AGAIN at the same time he’s talking about declaring insurrections and jailing more political opponents, like Mayor Johnson and Governor Pritzker and any one of a dozen judges including at least one he appointed – not prosecuting them, just jailing them - and, as if it could GET any worse, he specifically segued from the issue of wanting to prove to God that he’s been good to how great all those weapons are at his naval base. The missiles are flying, hallelujah, hallelujah. Plus he's written: “Chicago Mayor should be in jail for failing to protect Ice Officers! Governor Pritzker also." Look, you and I know it should be TRUMP in jail because he’s not only broken laws, he’s nearly COLLECTED THE COMPLETE SET of broken laws. But the process of convincing Trump that he's not crazy, that his predictions are coming true, that Portland is ablaze, is how Stephen Miller and the others manipulate him into eroding American democracy a little more every damn day. And this has worked since at least 2016 and I was told about it by Ed Rollins in 2017. It's the Trump personal feedback loop. And when the interruptors in that loop get in the way, they get bought out and destroyed. CNN first, The Washington Post, and now CBS News and the "B" stands for "Bari Weiss" who once told The Federalist Society that it was ok if it didn't believe her and her wife's marriage was legal because they all shared what really mattered: a desire for lower taxes. Let me expand upon the death of CBS News and her disastrous debut at its helm by retelling the story of the miniature version enacted at the CBS flagship station in LA when I worked there in 1991: The Mystery Of The Broken Number 3 CBS Pencils. B-Block (37:00) THE WORST PERSONS IN THE WORLD: What is wrong with these dweeb MAGAs? Ken Paxton can't keep his pants on, every other day there's some new story causing his wife to again decide to divorce him, and he's just announced "undercover operations" against leftists. Hey, Pal, if you did anything BESIDES undercover operations you wouldn't be dismissed as a sex pest. Poor Derrick Van Orden continues his descent: now he's yelling at people for not learning how the Senate votes the way he learned about it in the 4th Grade (all of what he learned was wrong). And the Bad Bunny Super Bowl blowback reaches Marjorie Taylor Greene who demands a law making English the official language which is going to be trouble for her since she doesn't speak it. C-Block (45:00) THURSDAYS WITH THURBER: It's one of those weeks, plus my back is gone, one of my eyes is fighting me: it's time to bring back the first Thurber story I ever read aloud to an audience, the oddly soothing "A Box To Hide In."See omnystudio.com/listener for privacy information.

Zwei Jahre nach der Terrorattacke des 7. Oktober eskaliert die Gewalt weiter. Millionen vertriebene Menschen, Hungersnot, unbefreite Geiseln, unversöhnlicher Zerstörungswille. Wie lässt sich ein schützender Ausweg denken: für Israel, die Palästinenser, das humanitäre Völkerrecht? Der barbarische Überfall des 7. Oktober 2023 markierte einen Wendepunkt: für Israel als Opfer des Angriffs, den Gaza-Streifen als dessen Ausgangsort sowie nicht zuletzt für die globale Geltung humanitären Völkerrechts. Zwei Jahre nach der Terrorattacke ist der Gaza-Streifen als Lebensraum für Millionen von Palästinensern nachhaltig zerstört, Dutzende israelischer Geiseln noch immer nicht befreit, wütet der Krieg weiter und überschreitet dabei, nach Wahrnehmung von immer mehr Staaten und Beobachtern, letzte ethische wie rechtliche Grenzen, zunehmend auch von Seiten Israels. Wie wäre ein Ausscheren aus der Gewaltspirale vorzustellen? Welche emotionalen, sozialen wie auch politischen Veränderungen wären dafür notwendig? Was bedeutet der immer konkreter im Raum stehende Verdacht eines genozidalen Vorgehens für das Selbstbild Israels, seine Aussenwahrnehmung, seine militärischen Allianzen? Steht «Gaza» gar als Symbol für ein kommendes Zeitalter unbedingten Kriegens jenseits aller geltenden Konventionen und Grenzen? Im Gespräch mit der Nahost-Expertin Muriel Asseburg und dem in Israel lebenden Politologen José Brunner sucht Wolfram Eilenberger nach Auswegen aus dem Bannkreis nicht enden wollender Gewalt.

SaVon and Alex are joined by Yassy and Eddin, and begin by explaining why full visuals are now on Patreon (0:00). After quick Patreon shout-outs, a listener question sparks a hilarious round of “most embarrassing moments,” from Savon's Santa stage slide to Alex's PAL game accident, with more clumsy stories from the group (8:59). They pivot to Bad Bunny headlining the Super Bowl LX halftime show, weighing his global pull, the “culture war” backlash, and why the NFL/Apple pairing makes sense (27:54). Later, the pod shifts into film talk—first with 'Him,' as well as other films, including the new Leonardo DiCaprio release, classics like 'Coco,' and the joys of going to the movies solo versus with company (44:21). From there, the discussion deep-dives into Young Thug's 'UY SCUTI'—Cardi B's standout verse, the controversial cover and hard-ER intro, and whether the project is rage-bait, a solid showing, or a genuine misstep (50:48). They critique the lack of theme, debate art vs. artist, and question if Thug is losing his standing in hip-hop. The conversation closes on Cardi B's place in rap—her verse of the year candidacy, feuding with Nicki Minaj, the Ice Spice/Latto comparisons, and whether Cardi is the true “Queen of New York” (1:13:10). Subscribe to our Patreon for EARLY & EXCLUSIVE access to ad-free episode visuals with music included, exclusive episodes each and every Tuesday, and much more! - www.patreon.com/NeedToKnowPodcast Book your next podcast recording at Need to Know Studios TODAY - https://needtoknowstudios.com/ Join our Twitter/X Community to chop it up with us about all things Need to Know - https://twitter.com/i/communities/1777442897001910433 The Need To Know Podcast Social Handles https://www.instagram.com/needtoknowpod/ https://twitter.com/NeedToKnowPod https://www.tiktok.com/needtoknowpod SaVon https://www.instagram.com/savonslvter/ https://twitter.com/SavonSlvter Alex https://www.instagram.com/balltillwefall/ https://twitter.com/balltillwefall

Das israelische Militär hat eine Flotte mit Hilfslieferungen für Palästinenser gestoppt und alle Aktivisten festgesetzt. Was will Israel nun mit ihnen tun? Und: Wie Europas Regierungen ihre Länder vor fremden Drohnen schützen wollen. (15:35) Grieß, Thielko

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

„Terribly human“ - Schrecklich menschlich, so heißt die Produktion einer freien internationalen Theatergruppe, die am Freitag und Samstag am Mannheimer Nationaltheater gastiert. Die Künstlerinnen und Künstler kommen aus Israel, Palästina, Syrien und Griechenland. Ihr Stück sollte eigentlich schon während der Schillertage gezeigt werden, aber die politische Lage hat einen Strich durch die Rechnung gemacht. Kleinbeigeben wollten aber weder die Theatergruppe noch das Nationaltheater.

Im Podcast „Amerika, wir müssen reden“ geht es um den Friedensplan von US-Präsident Donald Trump. Jiffer Bourguignon und Ingo Zamperoni analysieren gemeinsam die 20-Punkte-Strategie und fragen sich, ob dadurch der langjährige Konflikt zwischen Israelis und Palästinensern überwunden werden kann. Trump selbst bezeichnet diesen Moment als „einen der größten Tage der Zivilisation“. „It takes two to tango“, betont Ingo, und verweist darauf, dass die Hamas nicht in die Verhandlungen eingebunden war und es fraglich ist, ob die Terrororganisation die Waffen ablegen wird. Auch Jiffer ist skeptisch und hinterfragt Trumps Rolle als Friedensstifter und dessen Anspruch, bereits sieben Konflikte beendet zu haben. Eine oberflächliche Lösung sei keine dauerhafte Lösung. „Das ist ein Trostpflaster, vielleicht eine kurze Pause.“ Im Podcast geht es auch um die Trauerfeier für Charlie Kirk. Jiffer fand es unverschämt, dass Trump nach der herzlichen Rede der Witwe wieder darüber gesprochen hat, warum er seine Gegner hasst. Eigentlich wäre es seine Aufgabe gewesen als Präsident, das Land zu vereinigen und nicht zu spalten, fügt Ingo hinzu. Beide sprechen auch über die Bedeutung der Meinungsfreiheit, die Sendepause für Jimmy Kimmel, die Rolle der Justiz bei der Anklage gegen Ex-FBI-Chef Comey und darüber, warum die Demokraten eventuell einen Shutdown verhindern wollen. Feedback bitte per eMail an podcast@ndr.de Was sieht der Gaza Friedensplan vor? https://www.tagesschau.de/ausland/asien/friedensplan-usa-gazastreifen-israel-100.html Jimmy Kimmel wieder überall zu sehen https://www.tagesschau.de/ausland/amerika/kimmel-tv-show-100.html In den USA droht der nächste Shutdown https://www.tagesschau.de/ausland/amerika/us-haushalt-shutdown-100.html Podcast-Tipp: Bosettis Woche mit Jagoda Marinic https://1.ard.de/extra-3-bosettis-woche

Confira nesta edição do JR 24 Horas: O governo de São Paulo criou um gabinete de crise para coordenar o combate à adulteração de bebidas alcoólicas e investigar os casos de intoxicação por metanol. Ao todo são 22 casos investigados, sendo que 5 podem ter resultado na morte das vítimas. Os números foram confirmados durante coletiva de imprensa realizada nesta terça-feira (30), no Palácio dos Bandeirantes. O governador Tarcísio de Freitas afirmou que, das cinco mortes suspeitas, apenas uma teve confirmação de intoxicação por metanol. As outras quatro ainda estão sob investigação. E ainda: Polícia Federal realiza grande operação contra roubo de cargas e caminhões em cinco estados.

Die Themen von Lisa und Matthis am 30.09.25: (00:00:00) Wahlpanne: Warum eine Siegerin bei der Kommunalwahl in NRW jetzt doch keine ist. (00:01:39) Nahost-Krieg: Was in Trumps Friedensplan für den Gaza-Streifen steht und was das für die Palästinenser:innen bedeuten könnte. (00:07:17) Cannabis-Bericht: Wie die Teil-Legalisierung den Cannabis-Konsum beeinflusst hat und ob der Schwarzmarkt dadurch wirklich bekämpft wird. (00:13:34) Phishing: Vor allem die Gen Z fällt offenbar auf die Online-Betrugsmasche rein. Wie wir Phishing erkennen können. Hier findet ihr den Phishing-Radar der Verbraucherzentrale: https://www.verbraucherzentrale.de/wissen/digitale-welt/phishingradar/phishingradar-aktuelle-warnungen-6059 Habt ihr Fragen oder Feedback? Schickt uns gerne eine Sprachnachricht an 0151 15071635 oder schreibt uns an 0630@wdr.de – und kommt gern in unseren WhatsApp-Channel: https://1.ard.de/0630-bei-Whatsapp Von 0630.

Laut Donald Trump ist es "einer der größten Tage der Zivilisation". Er hat einen Plan vorgestellt, der den Krieg in Gaza beenden soll. Dazu gehört, dass alle Geiseln freikommen und Israels Truppen Gaza verlassen. Wie realistisch ist das? **********Ihr hört: Moderation: Rahel Klein Gesprächspartner: Jörg Poppendieck, ARD-Korrespondent im Studio in Tel Aviv in Israel Gesprächspartner: Shai Hoffmann, Aktivist und Podcaster "Über Israel und Palästina sprechen"**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .**********Ihr habt Anregungen, Wünsche, Themenideen? Dann schreibt uns an Info@deutschlandfunknova.de

(01:00): Zionistformand mener ikke, at tiden er til at anerkende Palæstina som stat. Medvirkende: Max Meyer, formand for Dansk Zionistforbund. (11:00): Minister gav urigtige oplysninger til Folketinget om dansk millioninvestering. Medvirkende: Toke Gripping, journalist, RADIO IIII. (30:00): Claus Jensen: Opslutningen af krigsskibe skal foregå i Danmark for at sikre arbejdspladser. Medvirkende: Claus Jensen, formand for Dansk Metal. Værter: Peter Marstal og Anne Phillipsen See omnystudio.com/listener for privacy information.

Die Themen von Caro und Lisa am 29.09.2025: (00:00:00) Lebensmittelrettung: Diese Woche gibt es mit "Zu gut für die Tonne" Aktionen gegen Verschwendung. (00:01:51) 12 Stunden Drohnen und Raketen: Russland hat die Ukraine am Wochenende schwer attackiert. Bei den Luftangriffen kamen vier Menschen ums Leben. (00:04:51) Oktoberfest: Das Gelände wurde Samstagabend kurzzeitig geschlossen, weil es zu voll war. Und sexuelle Übergriffe sind wieder ein Problem. (00:10:21) Gaza-Demo: In Berlin haben mindestens 60.000 Menschen für Palästina demonstriert - so viele wie noch nie. (00:15:17) Stichwahlen in NRW: Die drei wichtigsten Ergebnisse der letzten Runde der Kommunalwahlen im bevölkerungsreichsten Bundesland. Kennt ihr schon unseren WhatsApp Channel? Den findet ihr hier: https://1.ard.de/0630-Whatsapp-Kanal Oder einfach diesen QR-Code abscannen: https://1.ard.de/0630-bei-Whatsapp Hat euch unsere Folge gefallen? Dann lasst uns gerne eine Bewertung da. Fragen, Kritik? Ihr erreicht uns unter der 0151 15071635 oder per Mail 0630@wdr.de Von 0630.

Anerkendelse af Palæstina som stat fyldte under FN's 80. generalforsamling. Frankrig, Australien, Canada og Storbritannien har alleredevalgt at anerkende Palæstina som stat. Og forud for FN's generalforsamling i New York valgte den danske udenrigsminister, Lars Løkke Rasmussen, at lægge "en klar linje" for, hvornår Danmark er klar til at gøre det samme. Kritikere kalder timingen en belønning til Hamas efter 7. oktober og mener, den udsætter våbenhvile i Gaza. Er kritikken berettiget? Og hvad betyder anerkendelsen for krigen eller tiden efter? Gæst: Kristian Mouritzen, international analytiker, Berlingske Vært: Anne Sofie AllarpSee omnystudio.com/listener for privacy information.

Die deutsche Außenpolitik steht unter Druck: Die regelbasierte liberale Weltordnung gerät ins Wanken und Europa muss seine Rolle neu definieren. Besonders das aggressive Vorgehen Israels im Gazastreifen empört viele europäische Staaten. Als Reaktion erkennen immer mehr Länder Palästina als Staat an. Und auch angesichts des russischen Angriffskrieges gegen die Ukraine steigt der Druck von den USA auf Europa, entschiedener gegen Russland vorzugehen und geschlossener zu handeln. Insbesondere von Deutschland wird Führung erwartet. Caren Miosga diskutiert mit ihren Gästen, wie viel Spielraum der Bundesregierung zwischen historischer Verantwortung, aktuellen Krisen und dem Anspruch, Europa zu einen, bleibt und welche Rolle Deutschland in einer Weltordnung spielen kann, die zunehmend von Machtpolitik geprägt ist.

Craving to Quit: A Randomized Controlled Trial of Smartphone App–Based Mindfulness Training for Smoking CessationIn this episode, Dr. Jud discusses the results of a pioneering randomized controlled trial on the efficacy of the Craving to Quit app for mindfulness-based smoking cessation. Drawing from the paper Craving to Quit: A Randomized Controlled Trial of Smartphone App–Based Mindfulness Training for Smoking Cessation, by Kathleen Garrison et al., the episode unpacks the impact of app-based mindfulness training on cravings and smoking behavior. While the app did not outperform controls in long-term abstinence, it demonstrated a promising ability to weaken the association between cravings and smoking. Dr. Jud explores the implications of these findings, emphasizing how leveraging mindfulness through technology offers a scalable, accessible option for tackling smoking addiction.Reference:Garrison, K. A., Pal, P., O'Malley, S. S., Pittman, B. P., Gueorguieva, R., Rojiani, R., Scheinost, D., Dallery, J., Brewer, J. A. Craving to Quit: A Randomized Controlled Trial of Smartphone App–Based Mindfulness Training for Smoking Cessation. Nicotine & Tobacco Research, 2018. https://doi.org/10.1093/ntr/nty126Let's connect on Instagram

Foi o adivinho Calcas quem revelou as duas primeiras exigências para que os gregos pudessem vencer Troia: trazer Neoptólemo, filho de Aquiles, e Filocteto, portador das flechas envenenadas que matariam Páris. Mas havia ainda uma terceira condição — e esta só poderia ser revelada por alguém de dentro das muralhas. É então que surge outro profeta: Heleno, filho do rei Príamo. Tomado de raiva por ter sido preterido como novo esposo de Helena, ele abandona a cidade e avisa aos gregos que precisavam roubar o Paládio, pequena estátua de madeira de Atena que protegia Troia, e que ficava dentro das muralhas. Ulisses assume a perigosa missão. Disfarçado de mendigo, infiltra-se na cidade e encontra Helena. Os dois conversam — cena que só conhecemos porque a própria Helena a relata, dez anos depois, na Odisseia.Acesse o material exclusivo: https://noitesgregas.com.br/apoiar

Es leben 700.000 Siedler in dem besetzten Palästinensergebiet, nun denkt Netanjahus Regierung über eine offizielle Übernahme nach. Doch der US-Präsident sagt, er werde es Israel nicht erlauben.

Confira no Morning Show desta sexta-feira (26): O primeiro-ministro de Israel, Benjamin Netanyahu, discursou na Assembleia Geral da ONU. Os comentaristas do Morning Show analisaram as expectativas para a fala do premiê. Mano Ferreira destacou que "a estratégia militar que Netanyahu insiste não conseguiu trazer de volta os reféns". O presidente dos Estados Unidos, Donald Trump, anunciou novas tarifas a partir de 1º de outubro. As medidas vão atingir a importação de produtos farmacêuticos brasileiros, de caminhões pesados, de móveis e de artigos de cozinha e banheiro. O governador de São Paulo, Tarcísio de Freitas (Republicanos), programou uma viagem a Brasília para se encontrar com o ex-presidente Jair Bolsonaro (PL). A especulação é de que a conversa possa definir se ele tentará a reeleição em São Paulo ou se disputará o Palácio do Planalto. O governador, porém, nega articulações políticas e afirma que irá “visitar um amigo e prestar solidariedade”. Essas e outras notícias estão no Morning Show desta sexta-feira.

OpenAI baut mit Oracle und Softbank 7-Gigawatt-Datacenter in Texas und Oracle nimmt 18 Milliarden Dollar Schulden für KI-Infrastruktur auf. Microsoft startet Publisher Content Marketplace für KI-Lizenzen. OpenAI führt ChatGPT Go in Indonesien ein und launcht Pulse-Feature für personalisierte Updates. EU eröffnet Kartellverfahren gegen SAP wegen Wartungsverträgen. Amazon zahlt 2,5 Milliarden Dollar wegen Prime-Kündigungspraktiken. YouTube reinstated gesperrte COVID- und Wahl-Channels. Tether strebt 500-Milliarden-Bewertung an. Meta verhandelt mit Google über Gemini für Werbung. Microsoft blockiert israelisches Militär wegen Massenüberwachung. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Intro & TED-Talk Wien (00:03:17) OpenAI Stargate 7-Gigawatt-Datacenter (00:07:15) Oracle 18 Mrd. Schulden für KI (00:10:15) Microsoft Publisher Marketplace (00:12:10) OpenAI ChatGPT Go Indonesien (00:17:24) OpenAI GDP-Eval Benchmark (00:26:17) ChatGPT Pulse Feature (00:29:57) Antifa-Hoax auf Threads (00:31:12) SAP EU-Kartellverfahren (00:34:21) Amazon 2,5 Mrd. Prime-Strafe (00:36:05) Apple gegen EU-Regulierung (00:39:11) YouTube reinstated Channels (00:43:19) Tether 500 Mrd. Bewertung (00:48:17) H-1B-Visa Ausnahmen (00:49:45) Meta-Google Gemini-Deal (00:50:31) xAI Grok für 42 Cent (00:52:55) Microsoft blockiert Israel Shownotes OpenAI Teams Up With Oracle– wired Oracle: 18 Milliarden Dollar Schulden für KI-Ausbau – manager-magazin.de Microsoft plant KI-Marktplatz für Verlage mit Copilot – axios.com OpenAI: GPT-5 auf menschlichem Niveau in vielen Berufen – techcrunch.com Nach Indien: OpenAI startet günstigen ChatGPT Go-Plan in Indonesien – techcrunch.com OpenAI möchte, dass Sie Ihren Tag mit ChatGPT Pulse beginnen – theverge.com SAP: Aktie unter Druck - EU-Kartellverfahren – manager-magazin.de Amazon zahlt Rekordsumme von 2,5 Milliarden Dollar – manager-magazin.de Apple fordert Abschaffung der EU-Digitalregeln – ft.com YouTube hebt Sperren von Creators wegen COVID-19 und Wahl-Inhalten auf – thehill.com Krypto-Riese Tether strebt $500 Milliarden Bewertung an – bloomberg.com Christopher Bloomstran über Tether: Fragen zur finanziellen Situation und fehlenden Prüfungen – x.com Trump-Administration schlägt neues H-1B-Visaverfahren vor – reuters.com Meta verhandelt mit Google über Gemini zur Verbesserung von Werbemaßnahmen – theinformation.com Musk's Grok KI für US-Regierungsbehörden zugelassen – bloomberg.com Microsoft blockiert Israels Nutzung seiner Technologie zur Massenüberwachung von Palästinensern – theguardian.com

In Berlin ist eine Groß-Demonstration zum Gaza-Krieg geplant. Der Violinist und Mitorganisator Michael Barenboim hat die Veranstaltung verteidigt und das Vorgehen Israels in dem von Palästinensern bewohnten Küstengebiet als Völkermord bezeichnet. In SWR Kultur erklärt der Konzertmeister des West-Eastern Divan Orchestra, mit der Veranstaltung wolle man für die Einhaltung der Menschenrechte der Palästinenser einstehen.

Nach der Anerkennung eines Palästinenserstaats durch Frankreich und fünf weitere europäische Länder, reagiert Israels Ministerpräsident Benjamin Netanjahu mit einer Stellungnahme.

Mercoledi croccante. Siamo di Flottiglia. Non decima.Daniele Capezzone e il tribunale dei Parenzo.Andrea Lombardi, streamer contro l'attivista pro Pal, NinaCaterina Collovati torna per parlare con Asia Vitale, sex worker che si è data al porno.

Der französische Präsident Emmanuel Macron hat während einer UN-Konferenz zur Zweistaatenlösung offiziell die Anerkennung eines Palästinenserstaats verkündet, um den Friedensprozess zwischen Israelis und Palästinensern zu stärken. Der Schritt erfolgt trotz des anhaltenden Gaza-Kriegs und der scharfen Kritik Israels sowie einiger westlicher Staaten

Der Schritt von Frankreichs Präsident Macron hat wohl keine direkten politischen Auswirkungen. Er ist aber dennoch ein Signal an die Palästinenser und an Israel.

Diese Woche wird in New York wieder Geschichte geschrieben. Die Staats- und Regierungschefs der Welt haben sich zur jährlichen Generalversammlung der Vereinten Nationen versammelt. Ein heißes Thema auf der Agenda ist ohne Frage der territoriale Konflikt zwischen Israel und Palästina.

Heute gibt der Bundesrat bekannt, wie hoch die Krankenkassenprämien für 2026 ausfallen werden. Verschiedene Beobachterinnen und Beobachter gehen von einem geringeren Anstieg als in den letzten Jahren aus. Zusätzlich dürften künftig Massnahmen greifen, um den Kostenanstieg zu dämpfen. Und: · Jimmy Kimmel darf wieder auf Sendung: Letzte Woche wurde die Sendung des US-Comedians abgesetzt, doch nun hat der Disney-Konzern mitgeteilt, dass seine Sendung ab heute wieder ausgestrahlt wird. · Der Bundesrat hat sich mit Vertreterinnen und Vertretern der Pharma-Branche getroffen. Diese fordern höhere Medikamentenpreise in der Schweiz. Gesundheitsministerin Elisabeth Baume-Schneider hat sich gewillt gezeigt, die Rahmenbedingungen zu prüfen. · UNO-Generalsekretär Antonio Guterres hat sich im Rahmen der UNO-Vollversammlung zu einer möglichen Zweistaaten-Lösung für den Nahen Osten geäussert: Ein eigener Staat für alle Palästinenserinnen und Palästinenser sei ein Recht – und nicht eine Belohnung.

Immer mehr Staaten erkennen Palästina als eigenen Staat an, jetzt unter anderem auch: Kanada, Großbritannien, Australien und Frankreich. Ein klares Zeichen vor der jährlichen UN-Vollversammlung, die gerade in New York läuft. BR-Journalist Clemens Verenkotte erzählt in dieser Folge, wie der internationale Druck auf die Regierung Netanjahu wächst, ob das den Krieg in Gaza stoppen könnte. Und welche Staaten stehen noch uneingeschränkt an Israels Seite? Er war viele Jahre Auslands-Korrespondent – unter anderem in Tel Aviv und Washington und ist Experte für Außen- und Sicherheitspolitik. In diesen früheren 11KM-Folgen geht es um den Krieg in Gaza und um den Nahost-Konflikt: https://1.ard.de/11KM_Podcast_Nahost Hier geht's zu “Lost in Nahost”, unserem Podcast-Tipp: https://www.ardaudiothek.de/sendung/lost-in-nahost-der-podcast-zum-krieg-in-israel-und-gaza/urn:ard:show:5ef19b01d54f725b/ Diese und viele weitere Folgen von 11KM findet ihr überall da, wo es Podcasts gibt, auch hier in der ARD Audiothek: https://www.ardaudiothek.de/sendung/11km-der-tagesschau-podcast/12200383/ An dieser Folge waren beteiligt: Folgenautor: Moritz Fehrle, Charlotte Horn Mitarbeit: Nicole Dienemann, Niklas Münch Host: David Krause Produktion: Viktor Fölsner-Veress, Ruth-Maria Ostermann und Lisa Krumme Planung: Nicole Dienemann und Hardy Funk Distribution: Kerstin Ammermann Redaktionsleitung: Fumiko Lipp und Lena Gürtler 11KM: der tagesschau-Podcast wird produziert von BR24 und NDR Info. Die redaktionelle Verantwortung für diese Episode liegt beim NDR.

Flere store lande melder ud, at de anerkender Palæstina som stat, men gør det overhovedet en forskel for palæstinenserne? Vi spiser langt fra De officielle Kostråd, især når det handler om bælgfrugter og kød. Tidligere vicepræsident Kamala Harris kaster mudder mod Biden i ny bog. Vært: Amalie Schroll Munk. Medvirkende: Ole Wæver, professor i International politik ved Københavns Universitet. Birgitte Borup, kulturkommentator og USA-kender, Berlingske.

Linktree: ⁠https://linktr.ee/Analytic⁠Join The Normandy For Additional Bonus Audio And Visual Content For All Things Nme+! Join Here: ⁠https://ow.ly/msoH50WCu0K⁠Analytic Dreamz Reacts to Palworld - Official Version 1.0, Pocketpair and The Future Update VideoDive deep into the latest Palworld developments with Analytic Dreamz as he breaks down Pocketpair's official update video on Version 1.0 and the road ahead. In this segment, Analytic Dreamz examines the announcement of Palworld's full launch exiting Early Access in 2026, highlighting the massive content pipeline including new islands, Pals, mechanics, and the highly anticipated World Tree expansion. Discover how Pocketpair is shifting focus to polish quirks, optimize performance, and refine gameplay for a smoother survival crafting experience, while teasing surprises in the upcoming winter update—though smaller than Feybreak's scale.Analytic Dreamz explores Pocketpair's future vision, from bolstering their publishing arm to support indie devs worldwide, to hints at experimental projects without diverting core resources from Palworld's evolution. Amid ongoing Nintendo patent challenges, learn how this roadmap ensures long-term innovation in co-op multiplayer monster-taming adventures. Whether you're a base-builder, Pal trainer, or gun-toting explorer, this reaction unpacks what Version 1.0 means for the game's 32 million+ players and why 2026 could redefine open-world survival RPGs.Stay tuned for Analytic Dreamz's candid takes on gameplay impacts, community feedback integration, and bold predictions for Palworld's post-launch era. Essential listening for fans tracking Pocketpair's ambitious trajectory.Support this podcast at — https://redcircle.com/analytic-dreamz-notorious-mass-effect/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Die Stimmung auf dem Palästina-Gipfel in der Uno-Generalversammlung ist aufgeladen. Knapp ein Dutzend westliche Länder anerkennen nun Palästina formell als Staat. Bei keinem anderen ein Thema entzünden sich die Gemüter in der Uno derart wie beim israelisch-palästinensischen Konflikt. Alle Themen (00:00) Intro und Inhaltsübersicht (01:26) Palästina-Gipfel: Die Emotionen kochen hoch (08:16) Nachrichtenübersicht (12:38) USA: Angriffe auf die Meinungsfreiheit (20:46) Monsterdebatte zur «10-Millionen-Schweiz» (24:41) Ständerat lehnt Halbierungsinitiative ab (29:09) 2024 so viel Atomstrom produziert wie noch nie (33:47) Neues Präventionsprojekt der römisch-katholischen Kirche (37:56) Kokain: Westafrika wird zu neuem Transit-Hotspot

US-Demokraten warnen vor dem »Weg in die Diktatur«. Streit über Anerkennung eines Palästinenserstaates. Und: Richterwahl, nächster Versuch. Das ist die Lage am Montagmorgen. Die Artikel zum Nachlesen: Mehr Hintergründe hier: »Mit ein bisschen Kreativität lassen sich viele Wege finden, politische Gegner einzuschüchtern« Mehr Hintergründe: Rechtsextremer israelischer Minister fordert Annexion des Westjordanlands Mehr Hintergründe hier: »Nichts ist gefährlicher als schwache Richter, denn sie werden ideologische Richter« +++ Alle Infos zu unseren Werbepartnern finden Sie hier. Die SPIEGEL-Gruppe ist nicht für den Inhalt dieser Seite verantwortlich. +++ Den SPIEGEL-WhatsApp-Kanal finden Sie hier. Alle SPIEGEL Podcasts finden Sie hier. Mehr Hintergründe zum Thema erhalten Sie mit SPIEGEL+. Entdecken Sie die digitale Welt des SPIEGEL, unter spiegel.de/abonnieren finden Sie das passende Angebot. Informationen zu unserer Datenschutzerklärung.

Heute mit Kommentaren zum wiederholten Eindringen russischer Kampfflugzeuge in den NATO-Luftraum und zur Trauerfeier für den ultrakonservativen Aktivisten Kirk. Zunächst geht es um die Anerkennung von Palästina als Staat durch weitere Länder. www.deutschlandfunk.de, Internationale Presseschau

Heute mit Stimmen zur Deutschen Bahn, die erstmals eine Frau an der Spitze bekommen soll. Kommentiert wird auch die Anerkennung von Palästina als Staat durch weitere Länder. Doch zunächst geht es um die Verletzung des NATO-Luftraums durch russische Kampfflugzeuge. www.deutschlandfunk.de, Presseschau

Die Themen: 80 Jahre UN; Drake, Klingbeil und Klum auf der Wiesn; UK, Kanada und Australien erkennen Palästinenserstaat an; Russisches Flugzeug löst Luftwaffenalarm über Ostsee aus; 15% mehr Anmeldungen für Wehrdienst; Harry Styles läuft Berlin-Marathon; Leo Neugebauer holt Zehnkampf-Gold; Pentagon führt offizielle Medienzensur ein; Regierung streitet über höhere Erbschaftssteuer; Ex-FDP-Star Vogel wird Personalchef bei Eurowings und Hotel zahlt Prämie für vor Ort gezeugte Kinder Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/ApokalypseundFilterkaffee

Australien erkennt Palästina als Staat an / Deutsche Eurofighter verfolgen russiches Militärflugzeug über der Ostsee / Behörden nehmen Untersuchungen zu Optus-Ausfall auf / Trump reist zu Charlie Kirks Gedenkfeier / Leichtathletik-WM: Leo Neugebauer holt Gold im Zehnkampf

In einer koordinierten Erklärung haben Kanada, Australien und das Vereinigte Königreich den Staat Palästina offiziell anerkannt – ein historischer Schritt, da erstmals zwei G7-Mitglieder diesen Weg gehen. Während die drei Länder auf Reformzusagen der Palästinensischen Autonomiebehörde verweisen, reagiert Israels Regierung mit scharfer Ablehnung und spricht von einer „Belohnung des Terrors“. Auch in den USA formiert sich Widerstand. Beobachter sehen in der Anerkennung vor allem ein symbolisches Signal – mit unklaren Folgen für die Realität im Nahostkonflikt.

Thema: Wie soll sich die internationale Gemeinschaft in der Palästina-Frage verhalten und warum will Österreich in den UNO-Sicherheitsrat?

Die Stimmung auf dem Palästina-Gipfel in der Uno-Generalversammlung ist aufgeladen. Knapp ein Dutzend westliche Länder anerkennen nun Palästina formell als Staat. Bei keinem anderen ein Thema entzünden sich die Gemüter in der Uno derart wie beim israelisch-palästinensischen Konflikt. Weitere Themen: «Keine 10-Millionen-Schweiz» oder «Nachhaltigkeitsinitiative» - so heisst die Volksinitiative der SVP, mit der die Zuwanderung in die Schweiz beschränkt werden soll. Derzeit debattiert der Nationalrat darüber, 115 Rednerinnen und Redner wollen sich äussern. Um gegen Missbrauchsprobleme vorzugehen, hat die römisch-katholische Kirche verschiedene Massnahmen vorgenommen. Meist im Fokus dabei: die Betroffenen. Nun startet die römisch-katholische Kirche des Kantons Zürich ein Pilotprojekt, das auf mögliche Täter abzielt.

Drei westliche Wirtschaftsmächte erkennen Palästina als eigener Staat an, Hunderttausende Menschen auf der Flucht vor israelischer Militäroffensive im Gazastreifen, Gedenkveranstaltung in den USA nach tödlichem Attentat auf ultrarechten Aktivisten Kirk, Diskussion über Digitalisierung oder Modernisierung des Staates, Trachtenumzug auf dem Münchener Oktoberfest, Ergebnisse der Fußball-Bundesliga, Abschluss der Leichtathletik-WM in Tokio, Das Wetter Hinweis: Die Beiträge zum Thema "Fußball" und "Leichtathletik" dürfen auf rechtlichen Gründen nicht auf tagesschau.de gezeigt werden.

Drei westliche Wirtschaftsmächte erkennen Palästina als eigener Staat an, Hunderttausende Menschen auf der Flucht vor israelischer Militäroffensive im Gazastreifen, Gedenkveranstaltung in den USA nach tödlichem Attentat auf ultrarechten Aktivisten Kirk, Diskussion über Digitalisierung oder Modernisierung des Staates, Trachtenumzug auf dem Münchener Oktoberfest, Ergebnisse der Fußball-Bundesliga, Abschluss der Leichtathletik-WM in Tokio, Das Wetter Hinweis: Die Beiträge zum Thema "Fußball" und "Leichtathletik" dürfen auf rechtlichen Gründen nicht auf tagesschau.de gezeigt werden.

Reaktion in Israel auf die Anerkennung eines Palästinenserstaates durch Großbritannien und weitere westliche Staaten, Gedenkstunde in den USA nach Attentat auf ultrarechten Aktivist Kirk, Der Sport, Das Wetter Hinweis: Die Beiträge zum Thema "Fußball" und "Leichtathletik" dürfen auf rechtlichen Gründen nicht auf tagesschau.de gezeigt werden.

Die meisten Staaten erkennen Palästina an – Deutschland nicht. Bundeskanzler Friedrich Merz steht vor der Herausforderung, zwischen Staatsräson, dem Druck der EU und der Solidarität mit Israel eine neue politische Linie zu entwickeln. Lau, Mariam www.deutschlandfunk.de, Kommentare und Themen der Woche

Reaktion in Israel auf die Anerkennung eines Palästinenserstaates durch Großbritannien und weitere westliche Staaten, Gedenkstunde in den USA nach Attentat auf ultrarechten Aktivist Kirk, Der Sport, Das Wetter Hinweis: Die Beiträge zum Thema "Fußball" und "Leichtathletik" dürfen auf rechtlichen Gründen nicht auf tagesschau.de gezeigt werden.

Riesige Trauerfeier für rechtskonservativen Aktivisten Charlie Kirk, Erste G7-Staaten erkennen Palästina an, Parteitag der CHP in der Türkei, Mountainbiker Nino Schurter tritt zurück

In this episode of LIGHT TALK with The Lumen Brothers and Sister, the Lumen Family interviews Lighting Entrepreneur and "Geezers of Gear" podcaster Marcel Fairbairn. In this episode, Marcel, Ellen, Steve, Dennis, and David discuss: Being the Poorest guy in Wellington;  GearSource; Musical roots; The "Rock Mass"; Early days at Martin; Crazy parties; PAL 1200 and RoboScan stories; Ticket Bots; Dining with Dinosaurs at LDI; Sin City Sessions; GearShare, Solving cross-rental gear problems with AI; X-Live; Know Your Customer;  Marcel's pandemic Zoom Happy Hours; Are we close to an AI Lighting Console?; and Words of wisdom for young lighting entrepreneurs.  Nothing is Taboo, Nothing is Sacred, and Very Little Makes Sense.

Bei der UN-Vollversammlung am 23. September wollen einflussreiche Länder wie Frankreich, Großbritannien, Belgien und Kanada einen Staat Palästina anerkennen. Der symbolische Akt weckt bei einigen Palästinensern im Westjordanland neue Hoffnung. Lelle, Eva www.deutschlandfunk.de, Hintergrund

Bei der UN-Vollversammlung am 23. September wollen einflussreiche Länder wie Frankreich, Großbritannien, Belgien und Kanada einen Staat Palästina anerkennen. Der symbolische Akt weckt bei einigen Palästinensern im Westjordanland neue Hoffnung. Lell, Eva www.deutschlandfunk.de, Hintergrund

Die Berichterstattung des russischen Fernsehens zum Gaza-Krieg bemüht sich um Objektivität. Es gibt keine emotionalisierenden Berichte. Palästinenser aus Gaza kommen fast nicht zu Wort. Viele Artikel in russischen Medien enden mit einem Absatz, in dem es um den „Beginn des Konfliktes“ geht, den Angriff der Hamas auf israelische Zivilisten im Oktober 2023. Warum ist dasWeiterlesen

Dr. Monty Pal and Dr. Mina Sedrak discuss the science behind cancer treatment-induced accelerated aging and the development of drug therapies and technologies aimed at helping older patients and cancer survivors. TRANSCRIPT Transcript: Cancer and Aging: Researching the Path to Longer, More Vibrant Lives Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Monty Pal. I am a medical oncologist and professor and vice chair of medical oncology here at the City of Hope Comprehensive Cancer Center. I am also host of this podcast. Today, we are going to be talking to somebody that I consider to be my little brother, if you will, in oncology, Mina Sedrak. Mina is an expert in the area of cancer and aging, which really includes the development of drug therapies and technologies that help enable older adults and survivors to live longer, healthier, and more vibrant lives. I am really excited to chat with him. He is an expert not just in cancer and aging but also breast cancer. He was my former colleague here at City of Hope before he moved over to the UCLA Jonsson Comprehensive Cancer Center, where he is an associate professor and director there of the Cancer and Aging Program. Dr. Sedrak's research involves mechanisms behind cancer treatment-induced accelerated aging and really aims to take this science into more of a therapeutic direction, which I am super, super excited about.  Mina, thanks so much for joining us today, and just FYI for our listeners, we have all of our disclosures in the transcript of this episode. Dr. Mina Sedrak: Thank you, Monty. Thank you, Dr. Pal, for having me. I am really excited to be here. Dr. Monty Pal: I feel like we have to go on a first-name basis here with how well we know each other. So Mina, you and I together have witnessed this evolution in cancer and aging. I mean, both of us worked together here with just a legendary figure in the field of geriatric oncology, I will call it, Dr. Arti Hurria, mentor to me, mentor to you, mentor to so many. Can you give us a sense of where cancer and aging has gone since the time that you and I started here together at City of Hope? Dr. Mina Sedrak: Dr. Hurria and her collaborators, Dr. [Willliam] Dale and Dr. [Supriya] Mohile, they were like huge pioneers in the field. They were one of the very first people to highlight the importance of looking at older adults beyond just their chronological age and their comorbidities and moving us beyond just seeing patients and making decisions using what we call the eyeball test. "Oh, this person looks fit or not fit, frail or robust," to really using objective measures to assess our patient's health status and incorporate that assessment into our evaluation of the treatment, prognostication, and discussions with our patients throughout the cancer continuum. And so that is what geriatric oncology has and continues to be, and it is a huge, important part. And their work has laid the foundation to show that when we look at our patients beyond just their chronological age and we look at their functional age, and we do these objective assessments, we can gain much more deeper information to tailor the treatment for our patient that is sitting in front of us, rather than do a prescriptive treatment or over- or undertreatment in that population. So that is sort of where the field is growing, and a lot of the work now is, how do we implement that? How do we put that into clinical practice? Dr. Monty Pal: Well, let me kind of spearhead that discussion, right? I have these moments when I go to the ASCO Annual Meeting – I remember this happened to me a while ago when Dr. Jennifer Temel presented that terrific work around early palliative care interventions, right? Or it even happened to me this year, right, when Dr. Christopher Booth presented the CHALLENGE trial around exercise and colon cancer. You know, these amazing, I am going to say simple, they are not simple, but they are simple interventions relative to, you know, some of the complex drugs and mechanisms that we are using nowadays that really help outcomes for our cancer patients. The big question becomes, how do you implement, right? But my understanding is that there are easy ways for us to take tools in cancer and aging and sort of plug them into our daily practice. Am I right about that? Dr. Mina Sedrak: Yes, and that is something that they are – the Cancer and Aging Research Group, which was founded by Dr. Hurria and now is co-led by Dr. Dale, Dr. Mohile, and Dr. [Heidi] Klepin, they have been incredible at really trying to develop practical tools, like the Practical Geriatric Assessment, which is now endorsed by the ASCO and other NCCN guidelines. And so, there are tools that are becoming more and more practical to help incorporate that into clinic.  Now, what might be practical in a resource-intensive setting may not be practical in some of the limited resources, whether it is rural and/or other countries where the resources may be more limited. So that is why Cristiane Bergerot, Enrique Soto, and others have been really working hard. There was actually a really beautiful paper that was just published in the Journal of Global Oncology, where they have shown that there are guidelines [ASCO Geriatric Assessment Global Guideline] about how to implement these tests, these tools, these assessments in clinical practice, even in different resource settings. So I think we are going to get to the future where this is much more – it is definitely important, but it is much more easily ‘incorporatable' into our practice. Dr. Monty Pal: Yeah, you know how close I am to Cris, and I was so proud when I saw that paper come out. That was really exciting. You know, I skimmed it. I have to tell you, I did not get into the weeds, but it was apparent to me that, you know, some of these geriatric oncology tools are things that, you know, I could probably plug and play into my practice where I am double- and triple-booked over, you know, most slots, right? I mean, I could still probably afford a little bit of time or maybe have, like, a nurse or an extender kind of help participate in the evaluation process. I thought that was, yeah, really, really interesting. Dr. Mina Sedrak: I will just say that at UCLA, we are working with Dr. Arash Naeim, who is a geriatric oncologist, and he has developed an AI platform where the assessments can be done by an AI computer. So it is like talking to your ChatGPT. They can talk to you, and for a few minutes, they will ask you the questions. So you do not even have to fill it out on a piece of paper. You could give the patient a little iPad, put them in a private room while they are waiting for their doctor, and get the results, and it is right there for you. And so, we have been trying to think about how can technology help with the completion of the assessment, at least doing that? And I think it is actually, it has been very cool. We did a pilot study. He is writing that up, and we are going to continue to do some of this exciting work. How do we think about AI in the context of this? And, you know, older adults, they are not like what they used to be. A lot of older adults are very familiar with and comfortable with phones and computers and iPads, much more so today than they were even at the time when Dr. Hurria was alive. Dr. Monty Pal: That is so interesting. You mentioned this, the AI approach is something I have been thinking about in this context because what if, for instance, you know, we have got video monitors all over our hospital, right? What if you are actually just taking a look at that patient as they make their way towards your clinic? Capture that video, use an AI algorithm to say, "Hey, you know, the timed get-up-and-go test in this patient is not particularly good based on what I am seeing here," right? There are so many ways that you could, you know, stir the pot and come up with creative ways to get these tests done. Dr. Mina Sedrak: That's right. And Arash is looking at also sensors. So he has some studies where he is putting sensors inside people's homes, where they would put them, like, on top of an Alexa app or the equivalent. A lot of people have these apps, and basically, they can sense how you are moving around and what you are doing, just movement-wise. And then they can collect that information to gain information about your life beyond just what we are seeing in the 20-minute visit in the clinic. Even when I do a walk test where I get gait speed or physical performance, short physical performance battery, the chair sit-up, those are oftentimes a single, cross-sectional, static measure. But what about the dynamic ability of capturing what has been happening for the last 7 days? What has been happening for the last 25 days between the visits, between the cycles of chemotherapy? And could that inform how I make decisions when I see patients and who do I need to target and identify? And so, we are very excited because really at UCLA, Arash is leading the technology efforts and thinking about implementation of these important measures and these important tools but leveraging new technology. And we do not want to be behind; we want to be ahead of the game. Dr. Monty Pal: I love that idea because there is a Hawthorne effect, isn't there, where you observe a process, and it naturally gets better. I mean, when you ask that patient to get up in the clinic and move, they are probably functioning to the best of their abilities, but we could probably learn a lot from just watching how fast that patient picks up a remote control at home. Some simple movement like that that is volitional would probably help out a ton. And I got to tell you, it is so funny when you mention Arash Naeim's name. I distinctly remember him serving as an attending on the wards when he was brand new at UCLA on faculty when I was a resident there. And his dad is a legendary hematopathologist, right? Dr. Mina Sedrak: I did not know that. Dr. Monty Pal: Yeah, yeah. Faramarz Naeim wrote the book on a lot of heme-path malignancies. Incredible guy. Very, very storied hematopathologist at UCLA.  I could probably go on this topic forever, but in the interest of time, I am going to shift to something that again, I could probably talk about forever, which is this area of senescence that you are involved in. You know, you had mentioned this to me, I am going to say during your outro from City of Hope and towards your transition to UCLA, it is such an exciting area. I mean, understanding the actual biologic process of aging and using those underpinnings to really sort of tailor therapy. So tell us where the state of the science is there with this body of work that you are doing. Dr. Mina Sedrak: As I said before, we have tools now to assess patients and to then do something about the deficits. So if a patient is falling, what we do is we refer them to physical therapy where they can do fall precautions and strength training to give them the information. But all of these supportive care interventions are very important. They are great. But they oftentimes are not targeting the root cause of why they are happening. And so that is really where I have been very interested in, how can we understand why is it that something like chemotherapy or immunotherapy is causing a decline in cognitive function or a decline in physical function? And so that has really led us to think about geriatric oncology rather than a discipline of older adults, but to think about aging as a physiologic process. We are all aging. As every day goes by, we are aging. And what that means is that our bodies are accumulating damage, the cells are being exposed to various stressors, and the repair mechanisms are declining. And as we get older, it is really more damage and less repair mechanism at the cellular molecular level. And it turns out that these processes of how our cells repair and respond to damage are fundamental processes of biological aging. And there has been a large amount of preclinical and now really exciting clinical work to show that there are hallmarks that could be used to assess the rate of which we age by looking at these processes. And that includes things like epigenetics, telomeres, inflammation, and something called ‘cellular senescence.' And we have been interested in my lab in senescence because it is a unique process that has an important role in aging, but it also has a really important role in cancer. Senescence is a cell state. Cells, when they are stressed, they respond to entering this state of senescence. The stress could come from anything. It could come from an oncogene activation. It could come from a reactive oxygen species. It could come from a direct damage to the cell. But it is a cell state, just like apoptosis, necrosis. Senescence is a state in which the cell, in response to that stressor, undergoes an arrest from the G to the S phase. And that arrest is oftentimes associated with a resistance to apoptosis. So then the cell does not die, but it is alive, and it remains metabolically active. And in fact, downstream pathways of these cell cycle inhibition of this G-to-S phase lead to the increase of these transcription factors in the chromatin and lead to the development of these pro-inflammatory factors. So these cells, which can occur in various tissues in the body, can continue to live despite having developed these changes, and then they secrete these proinflammatory molecules like cytokines, chemokines, metalloproteinases, all of these, which are called the senescence-associated secretory phenotype, or SASP. And as we age, we accumulate more and more of these cells, and our bodies are no longer able – our immune system, like macrophages and T cells – are no longer able to remove them effectively. And as we accumulate them in various organs, these organs release a lot of inflammatory cytokines, and the chronic inflammation in that tissue leads to the tissue being damaged, and it does not work as well, and then it starts to decline in function. And that is believed to be how senescence plays a role in aging. It is the accumulation of senescent cells that occurs with increased damage and then the repair mechanism of clearing these cells effectively, which then leads to build up of inflammation and chronic inflammation leads up to damage in multiple tissues. Dr. Monty Pal: This concept to me is fascinating. And I guess the big question is – senescence is bad, right – is it not reasonable to think that this body of research, I mean, if you are able to sort of have a meaningful impact on senescence, it could have implications well beyond oncology. Is that fair? You really could extend lifespan all around. Is that reasonable to think, all-cause mortality? Dr. Mina Sedrak: One hundred percent. And that is what they have been shown in animal models. And the reason senescence is exciting is because it turns out that you can target these cells and you can induce apoptosis of these cells, but it requires active targeting of various pathways, but it can occur. And when it does, and it is done either genetically or pharmacologically in mice, we see that the mice can reverse damage. So if you take an old mouse and you genetically engineer it to remove senescent cells, that mouse will go from being frail to fit. And if you take a young mouse and you induce senescent cells at a high rate and you accumulate them in that mouse, that mouse, even though it is young, will become frail.  So that has really led to this exciting opportunity of, can we translate this finding that we are seeing in animals and in in vivo cells, cell cultures, into humans? And could that have a benefit beyond just one disease? Could it have a benefit in multiple diseases? And not just really longevity, which I think it would be great, but what people are really looking for is, how do we live healthy as we get older? How do we move the curve so that people are not developing chronic diseases in their 60s, but they are developing them in their 80s towards shortening the period of their life with disability rather than what we have currently, which is people are living to 70s, the average life expectancy is in the mid-70s, but they are spending 10 or 11 years in disability of that life. And so, how could we reduce that time frame? Dr. Monty Pal: This is brilliant, Mina. And for our audience, this compelling dialogue that we have had here thankfully is translating to funding for Mina's work. He just scored in the second percentile for his NIH R01 based on this topic. We are so, so proud of you. I mean, it is just remarkable work. It is not easy in the current climate to get funding, and a second percentile score is just absolutely wonderful. You know, Mina, I could probably go on with you for a couple more hours here talking about your work in cancer and aging. I think I am going to have to have you back on the podcast here. But a million thanks for sharing your thoughts here today on the ASCO Daily News Podcast.  And thanks to our listeners too. If you value the insights that you heard today on the ASCO Daily News Podcast, please do not forget to rate, review, and subscribe wherever you get your podcasts. Thanks, Mina. Dr. Mina Sedrak: Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Sumanta (Monty) Pal   @montypal  Dr. Mina Sedrak @minasedrakmd   Follow ASCO on social media:      @ASCO on Twitter     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Mina Sedrak: Patents, Royalties, Other Intellectual Property: Up-to-Date

Israel weitet Offensive gegen Palästinenser in Gaza aus, Gaza-Offensive löst international Kritik aus, Russische Drohne über Polens Regierungsgebäude unschädlich gemacht, Antrittsbesuch von Polens Präsident Nawrocki in Berlin, Gipfel über Zukunft des deutschen Maschinenbaus, Lebenslang in besonders schwerem Fall nach Messerattacke auf Polizisten in Mannheim, Ermittlungen gegen Ex-BND-Chef Hanning in Entführungs-Fall gegen Block-Erbin, Schauspieler Robert Redford im Alter von 89 Jahren gestorben, Ozonschicht erholt sich weiter, Das Wetter